Goat IgG anti-Human IgA-FITC, MinX none

Artikelnummer: DNA-SEC-183015
Artikelname: Goat IgG anti-Human IgA-FITC, MinX none
Artikelnummer: DNA-SEC-183015
Hersteller Artikelnummer: SEC-183015
Alternativnummer: DNA-SEC-183015
Hersteller: dianova
Wirt: Goat
Kategorie: Antikörper
Applikation: FLISA,FACS,IF
Spezies Reaktivität: Human
Immunogen: Human IgA alpha heavy chain
Konjugation: FITC
Alternative Synonym: goat anti-Human IgA (alpha chain) fluorescein conjugated Antibody, goat anti-Human IgA alpha Antibody FITC conjugation
Format: IgG
Spezifität: IgA
Minimale Kreuzreaktivität (MinX): no cross-adsorbtion
Anti-Human IgA Fluorescein Antibody generated in goat detects immunoglobulin A (alpha chain) from human. Immunoglobulin A (IgA) is an antibody that plays a critical role in mucosal immunity. IgA has two subclasses (IgA1 and IgA2) and can exist in a dimer
Klonalität: Polyclonal
Konzentration: 1.0 mg/mL
Isotyp: Ig
Puffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Reinheit: This product was prepared from monospecific antiserum by immunoaffinity chromatography using antigens coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.   Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein, anti-Goat Serum, Human IgA and Human Serum.  Specificity was confirmed by ELISA minimal cross reactivity against other human heavy or light chain isotypes.
Formulierung: Lyophilized
Formel: 20 mM K3PO4,150 mM NaCl,pH 7,2,lyophilisate,0,01% NaN3
Target-Kategorie: Human
Antibody Type: Secondary Antibody
Application Verdünnung: FLISA Dilution: 1:10,000 - 1:50,000, Flow Cytometry Dilution: 1:500 - 1:2,500, Fluorochrome Protein Value: 2.1, IF Microscopy Dilution: 1:1,000 - 1:5,000
Anwendungsbeschreibung: Anti-Human IgA Fluorescein Antibody is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.